ENABLEX Drug Patent Profile
✉ Email this page to a colleague
When do Enablex patents expire, and what generic alternatives are available?
Enablex is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in ENABLEX is darifenacin hydrobromide. There are nineteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the darifenacin hydrobromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Enablex
A generic version of ENABLEX was approved as darifenacin hydrobromide by CIPLA on September 1st, 2016.
Summary for ENABLEX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 120 |
Clinical Trials: | 16 |
Patent Applications: | 3,294 |
Drug Prices: | Drug price information for ENABLEX |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ENABLEX |
What excipients (inactive ingredients) are in ENABLEX? | ENABLEX excipients list |
DailyMed Link: | ENABLEX at DailyMed |
Recent Clinical Trials for ENABLEX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Astellas Scientific & Medical Affairs, Inc. | |
Universidad de Valparaiso | Phase 3 |
Recalcine (GynoPharm) | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for ENABLEX
Paragraph IV (Patent) Challenges for ENABLEX
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ENABLEX | Extended-release Tablets | darifenacin hydrobromide | 7.5 mg and 15 mg | 021513 | 3 | 2008-12-22 |
US Patents and Regulatory Information for ENABLEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | ENABLEX | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 021513-001 | Dec 22, 2004 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Abbvie | ENABLEX | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 021513-002 | Dec 22, 2004 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ENABLEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | ENABLEX | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 021513-002 | Dec 22, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | ENABLEX | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 021513-002 | Dec 22, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | ENABLEX | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 021513-001 | Dec 22, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbvie | ENABLEX | darifenacin hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 021513-001 | Dec 22, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for ENABLEX
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
pharmaand GmbH | Emselex | darifenacin hydrobromide | EMEA/H/C/000554 Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome. |
Authorised | no | no | no | 2004-10-22 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ENABLEX
See the table below for patents covering ENABLEX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 1023007 | ⤷ Try a Trial | |
Luxembourg | 91161 | ⤷ Try a Trial | |
Brazil | 9610153 | ⤷ Try a Trial | |
Netherlands | 300191 | ⤷ Try a Trial | |
Israel | 122746 | Pharmaceutical formulations containing darifenacin | ⤷ Try a Trial |
Norway | 901241 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ENABLEX
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0388054 | 91161 | Luxembourg | ⤷ Try a Trial | 91161, EXPIRES: 20150302 |
0850059 | CA 2005 00020 | Denmark | ⤷ Try a Trial | |
0388054 | CA 2005 00019 | Denmark | ⤷ Try a Trial | |
0388054 | 300191 | Netherlands | ⤷ Try a Trial | 300191, 20100302, EXPIRES: 20150301 |
0388054 | 05C0017 | France | ⤷ Try a Trial | PRODUCT NAME: DARIFENACINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI CI; REGISTRATION NO/DATE IN FRANCE: EU/1/04/294/001 DU 20041022; REGISTRATION NO/DATE AT EEC: EU/01/04/294/001-012 DU 20041022 |
0850059 | 22/2005 | Austria | ⤷ Try a Trial | PRODUCT NAME: DARIFENACIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ HIEVON; REGISTRATION NO/DATE: EU/1/04/294/001- EU/1/04/294/012 20041022 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |